Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Heigener

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Deutsche Medizinische Wochenschrift (1946)|March 4, 2015
[Non-small cell lung cancer: news from immunotherapy]Niels Reinmuth, David F Heigener, Martin Reck
The Lancet. Respiratory Medicine|March 25, 2015
Targeting of MEK in lung cancer therapeuticsDavid F Heigener, David R Gandara, Martin Reck
Clinical Lung Cancer|November 21, 2016
Second-Line Treatment Selection in Patients With Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating PhysiciansNicolas Girard, Jesus Corral, Diego Cortinovis, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and GermanyHelge G Bischoff, David F Heigener, Stefan Walzer, et al.
Lancet (London, England)|August 27, 2013
Management of non-small-cell lung cancer: recent developmentsMartin Reck, David F Heigener, Tony Mok, et al.
Lung Cancer (Amsterdam, Netherlands)|March 29, 2011
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST studyDavid F Heigener, Yi-Long Wu, Nico van Zandwijk, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 21, 2012
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerAlain Vergnenègre, Joshua A Ray, Christos Chouaid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2019
Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung CancerDavid F Heigener, Keith M Kerr, Gavin M Laing, et al.
The Oncologist|September 11, 2015
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR InhibitorsDavid F Heigener, Christian Schumann, Martin Sebastian, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancerDavid F Heigener, Joachim von Pawel, Corinna Eschbach, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Deutsche Medizinische Wochenschrift (1946)|March 4, 2015
[Non-small cell lung cancer: news from immunotherapy]Niels Reinmuth, David F Heigener, Martin Reck
The Lancet. Respiratory Medicine|March 25, 2015
Targeting of MEK in lung cancer therapeuticsDavid F Heigener, David R Gandara, Martin Reck
Clinical Lung Cancer|November 21, 2016
Second-Line Treatment Selection in Patients With Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating PhysiciansNicolas Girard, Jesus Corral, Diego Cortinovis, et al.
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and GermanyHelge G Bischoff, David F Heigener, Stefan Walzer, et al.
Lancet (London, England)|August 27, 2013
Management of non-small-cell lung cancer: recent developmentsMartin Reck, David F Heigener, Tony Mok, et al.
Lung Cancer (Amsterdam, Netherlands)|March 29, 2011
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST studyDavid F Heigener, Yi-Long Wu, Nico van Zandwijk, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 21, 2012
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerAlain Vergnenègre, Joshua A Ray, Christos Chouaid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2019
Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung CancerDavid F Heigener, Keith M Kerr, Gavin M Laing, et al.
The Oncologist|September 11, 2015
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR InhibitorsDavid F Heigener, Christian Schumann, Martin Sebastian, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancerDavid F Heigener, Joachim von Pawel, Corinna Eschbach, et al.
Pageof 3